Abstract:Bone morphogenetic proteins (BMPs) are secreted cytokines that were initially discovered on the basis of their ability to induce bone. Several decades of research have now established that these proteins function in a large variety of physiopathological processes. There are about 15 BMP family members, which signal via three transmembrane type II receptors and four transmembrane type I receptors. Mechanistically, BMP binding leads to phosphorylation of the type I receptor by the type II receptor. This activated heteromeric complex triggers intracellular signaling that is initiated by phosphorylation of receptor‐regulated SMAD1, 5, and 8 (also termed R‐SMADs). Activated R‐SMADs form heteromeric complexes with SMAD4, which engage in specific transcriptional responses. There is convergence along the signaling pathway and, besides the canonical SMAD pathway, BMP‐receptor activation can also induce non‐SMAD signaling. Each step in the pathway is fine‐tuned by positive and negative regulation and crosstalk with other signaling pathways. For example, ligand bioavailability for the receptor can be regulated by ligand‐binding proteins that sequester the ligand from interacting with receptors. Accessory co‐receptors, also known as BMP type III receptors, lack intrinsic enzymatic activity but enhance BMP signaling by presenting ligands to receptors. In this review, we discuss the role of BMP receptor signaling and how corruption of this pathway contributes to cardiovascular and musculoskeletal diseases and cancer. We describe pharmacological tools to interrogate the function of BMP receptor signaling in specific biological processes and focus on how these agents can be used as drugs to inhibit or activate the function of the receptor, thereby normalizing dysregulated BMP signaling. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Overactive Bone Morphogenetic Protein Signaling in Heterotopic Ossification and Duchenne Muscular Dystrophy

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

BMP Signaling in the Development and Regeneration of Cranium Bones and Maintenance of Calvarial Stem Cells.

Bone Morphogenetic Protein Signaling in Bone Homeostasis.

Bone morphogenetic protein signaling in bone homeostasis

Bone Morphogenetic Protein (BMP) signaling in development and human diseases

Bone Morphogenetic Protein Receptor Signal Transduction in Human Disease

BMP signaling in vascular diseases.

The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease

BMP Signaling in Vascular Diseases

BMP Signaling in Osteogenesis, Bone Remodeling and Repair

TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease

The BMP Pathway and Its Inhibitors in the Skeleton

Bone Morphogenetic Protein-Smad Pathway As Drug Targets for Osteoporosis and Cancer Therapy

Signal Transduction of Bone Morphogenetic Proteins in Osteoblast Differentiation.

Bone morphogenetic protein signaling in inflammation

Bone Morphogenetic Proteins In The Initiation And Progression Of Breast Cancer

Bone Morphogenetic Protein Receptors: Structure, Function and Targeting by Selective Small Molecule Kinase Inhibitors

BMP Antagonists Enhance Myogenic Differentiation and Ameliorate the Dystrophic Phenotype in a DMD Mouse Model

Deregulated Bone Morphogenetic Protein Receptor Signaling Underlies Fibrodysplasia Ossificans Progressiva.

When BMP Signalling Goes Wrong: the Intracellular and Molecular Mechanisms of BMP Signalling in Cancer